RE:RE:RE:AEZS and CZONo doubt that when I first heard that Gilles joined AEZS in January that I believed he wanted to fast track CZO onto NASDAQ.
However, keep in mind that AEZS was losing its eligibility based on its share price, and now trading under $1 with the impact of the financing, the timing isn't there now, but could be there later.
A COVID 19 treatment would be a gold mine, I wouldn't want to see a "non-arms length" deal. Hopefully with a PGX deal / human trials on the COVID 19 therapeutic around December, we shall see CZO at a much higher cap. Perhaps in mid to late 2021, CZO could merge with AEZS to get a NASDAQ listing, though I don't think it would be that urgent if CZO is successful in H2 2020 with their pipeline. Keep in mind that results on the BG pill will be out in H2 2021.
I'd rather see CZO remain solo that dilute itself with what I percieve is a much weaker, one product,much lower potential company.
westcoast1000 wrote: I certainly agree with Digitel that Gilles has plenty (in fact far too much) on his plate without joining another ocmpany. that is weird.
the notion of a merger of the companies is not completely far fetched.
Finally, selling off either the diabetes or the covid opportunity could be very wise if they license the pdx technology into the deal.
In general Gilles must be wildly overextended with all the stuff going on that never seems to move forward with speed.